The PSMA-1 ligand is further modified for in situ synthesis of PSMA-targeted Au25 clusters (CY-PSMA-1-Au25), providing a high-affinity and highly effective radiosensitizer for prostate cancer (Luo et al., 2012). Here, FOLH1 is linked to prostate cancer.